{"id":56685,"date":"2026-02-09T21:30:56","date_gmt":"2026-02-09T13:30:56","guid":{"rendered":"https:\/\/flcube.com\/?p=56685"},"modified":"2026-02-09T21:30:58","modified_gmt":"2026-02-09T13:30:58","slug":"sino-biopharm-completes-phase-iii-enrollment-for-lm-302-adc-in-gastric-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56685","title":{"rendered":"Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer"},"content":{"rendered":"\n

Sino Biopharmaceutical Ltd<\/strong> (HKG: 1177<\/a><\/strong>) announced completion of patient enrollment<\/strong> for the registrational Phase III clinical study (LM302-03-101)<\/strong> evaluating LM-302<\/strong>, a CLDN18.2-targeting antibody-drug conjugate (ADC)<\/strong>. The trial targets third-line or higher CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma<\/strong>, positioning LM-302 for potential first-in-class ADC approval<\/strong> in this high-unmet-need gastrointestinal malignancy.<\/p>\n\n\n\n

Clinical Trial Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Sino Biopharmaceutical Ltd (HKG: 1177)<\/td><\/tr>
Subsidiary<\/strong><\/td>LaNova Medicines Limited (Shanghai-based; acquired July 2024)<\/td><\/tr>
Asset<\/strong><\/td>LM-302 \u2013 CLDN18.2-targeting ADC (Category 1 drug)<\/td><\/tr>
Study<\/strong><\/td>LM302-03-101 \u2013 Phase III registrational trial<\/td><\/tr>
Status<\/strong><\/td>Patient enrollment completed<\/td><\/tr>
Indication<\/strong><\/td>Third-line+ CLDN18.2-positive gastric\/GEJ adenocarcinoma<\/td><\/tr>
Mechanism<\/strong><\/td>ADC targeting tight junction protein CLDN18.2, highly expressed in gastric\/pancreatic\/biliary tumors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Global Licensing History & Strategic Evolution<\/h2>\n\n\n\n
Timeline<\/th>Event<\/th>Strategic Implication<\/th><\/tr><\/thead>
May 2022<\/strong><\/td>LaNova Med licenses LM-302 ex-China\/South Korea rights to Turning Point Therapeutics<\/strong> (US)<\/td>Validation of global ADC potential<\/td><\/tr>
June 2022<\/strong><\/td>Bristol Myers Squibb acquires Turning Point<\/strong>, inherits LM-302 rights<\/td>Big Pharma recognition of asset value<\/td><\/tr>
October 2024<\/strong><\/td>BMS returns LM-302 rights to LaNova Med<\/strong><\/td>Sino Biopharm regains full global control via subsidiary acquisition<\/td><\/tr>
July 2024<\/strong><\/td>Sino Biopharm acquires LaNova Medicines<\/strong><\/td>Consolidates ADC pipeline and regains ex-China rights<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Target Indication & Unmet Need<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th>Strategic Significance<\/th><\/tr><\/thead>
Gastric Cancer Burden<\/strong><\/td>~1 million new cases annually in Asia; CLDN18.2 expressed in ~40% of gastric adenocarcinomas<\/strong><\/td>Large addressable biomarker-defined population<\/td><\/tr>
Third-Line Setting<\/strong><\/td>No standard of care; median survival <6 months<\/strong><\/td>High-unmet-need indication with accelerated approval pathway eligibility<\/td><\/tr>
CLDN18.2 Competition<\/strong><\/td>Zolbetuximab (Astellas\/Ipsen) approved in 2024 as naked antibody; no approved ADCs<\/td>LM-302 offers potentially superior efficacy<\/strong> via cytotoxic payload delivery<\/td><\/tr>
Pipeline Expansion<\/strong><\/td>Active development in pancreatic cancer and biliary tract cancer<\/strong><\/td>Platform potential across gastrointestinal malignancies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Positioning & Commercial Outlook<\/h2>\n\n\n\n